Etanercept biosimilar (AvesthaGen)

依那西普生物类似药 (AvesthaGen)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEtanercept biosimilar (AvesthaGen)

Drug Alias Name依那西普生物仿制药 (AvesthaGen)Etanercept (AvesthaGen)Etanerceptum (AvesthaGen)Avent

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein

Mechanisms of ActionTumor necrosis factor β inhibitorsTumor necrosis factor α inhibitors

TargetsTumor necrosis factor βTumor necrosis factor α

Therapy Area/IndicationsArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAvesthagen

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesAvesthagen

Active IndicationsN/A

Inactive IndicationsArthritis, Rheumatoid

ATC CodeL04AB01